Mean area under the curve (AUC) of SARS-CoV-2 viral load in Part B study participants;Mean area under the curve (AUC) of SARS-CoV-2 viral load in Part C study participants;Occurrence of adverse events (AEs) in Part A participants;Occurrence of adverse events of special interest (AESIs) in Part A participants;Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) in Part A participants readings;Occurrence of disease progression events (not classified as AEs) in Part A participants;Occurrence of serious adverse events (SAEs) in Part A participants

Mean area under the curve (AUC) of SARS-CoV-2 viral load in Part B study participants;Mean area under the curve (AUC) of SARS-CoV-2 viral load in Part C study participants;Occurrence of adverse events (AEs) in Part A participants;Occurrence of adverse events of special interest (AESIs) in Part A participants;Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) in Part A participants readings;Occurrence of disease progression events (not classified as AEs) in Part A participants;Occurrence of serious adverse events (SAEs) in Part A participants

Occurrence of adverse events (AEs);Occurrence of adverse events of special interest (AESIs);Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) readings;Occurrence of disease progression events (not classified as AEs);Occurrence of serious adverse events (SAEs)

Occurrence of adverse events (AEs);Occurrence of adverse events of special interest (AESIs);Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) readings;Occurrence of disease progression events (not classified as AEs);Occurrence of serious adverse events (SAEs)